Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical- …